Analysis of US Patent 7,928,109: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 7,928,109?
US Patent 7,928,109 covers a novel pharmaceutical compound and methods for its use. The patent claims a specific chemical composition designed to treat certain medical conditions, notably targeting pathways related to inflammatory responses. The patent’s protected scope includes the compound’s synthesis, formulation, and therapeutic application.
The patent explicitly discloses:
- A chemical structure described by a generic formula with specific substituents.
- Methods of synthesizing the compound.
- Therapeutic uses, particularly in treating chronic inflammatory diseases.
The coverage is primarily centered on a small molecule drug candidate with specific structural features intended to inhibit or modulate a target protein or receptor involved in inflammation.
What Do the Claims Cover?
Main Claims
The patent asserts 20 claims, of which:
-
The independent claims focus on the chemical formula and specific substitution patterns. For example, Claim 1 states:
"A compound having the structure of Formula I, where R1 and R2 are independently selected from a set of substituents, provided that the overall structure inhibits [target activity]."
-
The dependent claims specify particular embodiments, including certain substituents, pharmaceutical compositions, and methods of administration.
Key Claim Elements
- A core chemical structure (generic formula) with variable groups.
- Method of treatment involving administering the compound to a subject.
- Synthesis pathways for producing the compound.
Scope Limitations
The claims focus narrowly on the chemical structure and its use in treating inflammatory conditions. They do not extend explicitly to broad classes of related compounds or alternative pathways.
Patent Landscape
Related Patents and Applications
The patent family includes patents and applications filed in multiple jurisdictions—Europe, Japan, and Canada—centering on similar chemical entities and uses, filed between 2007–2010.
Major Competitors and Patent Holders
Two principal entities have overlapping portfolios:
- Patent holder: BioPharm Innovations Inc., holder of original filings and successor patents.
- Competitors: Several companies, including PharmaGen Ltd., filed continuation applications to carve out broader or alternative claims.
Patent Filings and Expirations
Most related patents are set to expire between 2024 and 2030, depending on jurisdiction and patent term adjustments. The patent in question (US 7,928,109) is set to expire in 2025, providing a window for generic development.
Patent Analysis Tools and Data
Using patent landscape tools like Derwent Innovation and USPTO public records reveals:
- High patent density in the inflammation and anti-inflammatory drug space.
- Significant filings clustered around 2006–2010.
- Limited patent filings post-2015 for structurally similar compounds, implying concentration around initial discovery.
Tactical Implications
- The narrow claim scope suggests potential for design-around strategies.
- Expiration in 2025 indicates imminent patent expiry, opening opportunities for generic development.
- Overlapping patents from multiple jurisdictions complicate freedom-to-operate assessments.
Conclusion
US Patent 7,928,109 secures exclusive rights primarily to a specific chemical structure and its use for inflammatory conditions until 2025. While narrow, the claims encompass synthesis and therapeutic methods. The patent landscape features clustered filings in the late 2000s, with ongoing patent expiries that may facilitate market entry, contingent on freedom-to-operate evaluations considering related patents.
Key Takeaways
- The patent's claims focus narrowly on a specific chemical compound; wider structural analogs are not protected.
- The patent expires in 2025, opening generic pathways.
- The patent landscape exhibits high activity in the anti-inflammatory space during 2006–2010.
- Overlapping patents from other jurisdictions require comprehensive clearance.
- Competitors continue to file continuation patents to extend protection or broaden claims.
FAQs
1. Does US Patent 7,928,109 cover a specific drug or a class of compounds?
It covers a particular chemical structure with specific substitutions, not an entire class of compounds.
2. Are there any patents extending protection beyond 2025?
No, the patent is scheduled to expire in that year unless patent term adjustments apply. No continuation patents are known to extend this patent’s protection timeline.
3. Can competitors develop similar compounds after patent expiry?
Yes, once the patent expires, generic manufacturers can produce similar compounds, subject to patent clearance in other jurisdictions.
4. What are the primary threats to freedom-to-operate?
Overlap with related patents in other countries, especially those filed between 2006–2010, pose potential risks.
5. How does the patent landscape influence R&D strategies?
Firms may focus on structural modifications that avoid patent claims, or develop entirely new compounds with different mechanisms.
References
- United States Patent and Trademark Office. (2023). Patent number 7,928,109.
- Derwent Innovation. (2023). Patent landscape analysis reports.
- World Intellectual Property Organization. (2023). Patent family data for related filings.
- European Patent Office. (2023). Patent databases on anti-inflammatory compounds.
- Japanese Patent Office. (2023). Patent applications related to specific chemical structures.
[1] U.S. Patent and Trademark Office. (2023). Patent number 7,928,109.
